EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non–Small Cell Lung Cancer: Systematic Review and Meta-Analysis

Ziqi Jiang, Yuan Xu, Shuyu Jia, Hongsheng Liu

Journal of Medical Internet Research · 13.08.2026 · 28 · e93892-e93892

DOI: 10.2196/93892 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Medical Internet Research, online erschienen am 13.08.2026. Verfasst von Ziqi Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, No.1 Shuaifuyuan, Wangfujing, Beijing, Don…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiomics, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non–small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Accurate early prediction of response to neoadjuvant therapy is critical.

Objective

We aimed to evaluate the diagnostic performance of radiomics-based AI in predicting pathological complete response (pCR) and major pathological response (MPR) following neoadjuvant immunochemotherapy in NSCLC and to compare it against traditional radiological criteria.

Methods

A systematic search of PubMed, Embase, Cochrane Library, and Web of Science was conducted through October 26, 2025. Studies utilizing computed tomography (CT) or positron emission tomography/CT-based AI models to predict pCR or MPR were included. Methodological quality was appraised using the PROBAST (Prediction Model Risk of Bias Assessment Tool)+AI tool. Sensitivity, specificity, and area under the curve (AUC) were pooled using a bivariate random effects model.

Results

Twenty-three studies involving 2004 patients in validation sets were included, with histopathology as the gold standard. For pCR, AI models achieved a pooled sensitivity of 0.77 (95% CI 0.70‐0.83), specificity of 0.79 (95% CI 0.73‐0.84), and AUC of 0.85, significantly outperforming traditional criteria in sensitivity (0.77 vs 0.42; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRadiomicsLung NeoplasmsNeoadjuvant TherapyArtificial IntelligenceImmunotherapyHumansPathologic Complete Response

Stichwörter der Autor:innen

NSCLCmeta-analysisneoadjuvant therapynon–small cell lung carcinomapathological responseradiomics

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, No.1 Shuaifuyuan, Wangfujing, Beijing, Dongcheng District, 100730, China, 86 13621021237.
  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Zitieren

APA

Jiang, Z., Xu, Y., Jia, S., & Liu, H. (2026). Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non–Small Cell Lung Cancer: Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 28, e93892-e93892. https://doi.org/10.2196/93892

Vancouver

Jiang Z, Xu Y, Jia S, Liu H. Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non–Small Cell Lung Cancer: Systematic Review and Meta-Analysis. Journal of Medical Internet Research. 2026;28:e93892-e93892. doi:10.2196/93892

BibTeX
@article{Jiang2026,
  author = {Jiang, Ziqi and Xu, Yuan and Jia, Shuyu and Liu, Hongsheng},
  title = {Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non–Small Cell Lung Cancer: Systematic Review and Meta-Analysis},
  journal = {Journal of Medical Internet Research},
  year = {2026},
  volume = {28},
  pages = {e93892--e93892},
  doi = {10.2196/93892}
}
Kostenlos starten →